The trial demonstrated significant improvement in eczema, also known as atopic dermatitis, for adolescents and children treated with Atopiclair cream, compared to an emollient vehicle cream.
Current treatments for eczema include topical corticosteroids or topical immunomodulators, which may have unfavorable side effects. Atopiclair is free from corticosteroids and immunomodulators.
The primary endpoint of the study was treatment success, defined by the patient being either clear or almost clear. Of the patients using Atopiclair, 80% were considered treatment successes, compared to 26% of patients receiving the emollient cream.
Secondary outcomes included the need for rescue medication, in the event of a flare-up. In the Atopiclair group, only one patient needed rescue medication with a steroid cream. No serious adverse events relating to Atopiclair were recorded in the study.
“About one third of atopic dermatitis prescriptions are for pediatric patients and we are pleased that these results reflect other studies, and confirm Atopiclair's usefulness for younger and more vulnerable patients,” said Professor Beradesca of the Istituto Dematologico San Gallicano in Italy.
Atopiclair has regulatory approval in both the EU and the US.